Omnicell, Inc. (NASDAQ:OMCL) Stock Has Average Price Target of $57.86

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $57.86.

A number of brokerages have weighed in on OMCL. Wells Fargo & Company lowered their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. KeyCorp restated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Piper Sandler restated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Finally, Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday.

Key Stories Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks Research upgraded Omnicell from “hold” to “strong-buy,” adding to the bullish analyst-rating momentum. Tickerreport article
• Positive Sentiment: Zacks cited solid earnings-estimate revisions as a reason OMCL may continue moving higher in the near term. Zacks earnings-estimate revisions article
• Positive Sentiment: OMCL was added to Zacks’ Rank #1 (Strong Buy) lists for momentum and value stocks, reinforcing the favorable assessment. Zacks momentum stocks article Zacks value stocks article
• Neutral Sentiment: A Zacks article noted that analysts’ consensus target implies substantial potential upside, but cautioned that price targets alone have limited predictive value; it also pointed to estimate revisions as a more encouraging signal. Zacks analyst price-target article

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nykredit A S bought a new position in Omnicell in the 2nd quarter worth approximately $26,000. Versant Capital Management Inc increased its stake in shares of Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after purchasing an additional 294 shares during the last quarter. Fulcrum Asset Management LLP increased its holdings in Omnicell by 2,536.4% in the third quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock worth $40,000 after purchasing an additional 1,116 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Omnicell during the second quarter worth $105,000. Finally, Nisa Investment Advisors LLC grew its position in Omnicell by 21.9% during the third quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock worth $89,000 after buying an additional 469 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Performance

Omnicell stock opened at $37.34 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.65 and a quick ratio of 1.45. Omnicell has a 1 year low of $31.75 and a 1 year high of $55.00. The company has a market capitalization of $1.70 billion, a P/E ratio of 38.90, a P/E/G ratio of 1.00 and a beta of 0.88. The business has a 50 day moving average of $34.93 and a 200-day moving average of $38.78.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The business had revenue of $307.85 million for the quarter, compared to analysts’ expectations of $304.44 million. During the same quarter in the previous year, the business posted $0.51 earnings per share. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. On average, equities research analysts predict that Omnicell will post 1.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.